Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review
CONCLUSION: Although SGLT2 inhibitors have been reported to have adverse effects on ketoacidosis, recent studies indicate that the occurrence of ketoacidosis is relatively rare. Considering the pathological mechanism of CPI-triggered diabetes, SGLT2 inhibitors could be an effective choice if they are administered while carefully monitoring the patient's ketoacidosis.PMID:38106883 | PMC:PMC10725247 | DOI:10.3389/fpubh.2023.1264056
Source: Cancer Control - Category: Cancer & Oncology Authors: Makoto Fujiwara Masaru Shimizu Tatsuya Okano Yuko Maejima Kenju Shimomura Source Type: research
More News: Cancer | Cancer & Oncology | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Endocrinology | Forxiga | Insulin | International Medicine & Public Health | Lung Cancer | Oral Cancer | SGLT2 Inhibitors | Sodium | Study | Yervoy